Interviews

Jonathan G. Marquess, PharmD, CDE, explains why going out of your way to serve diabetes patients can help grow your pharmacy's business.

Joe Moose, PharmD, discusses the importance of working with physicians and other health care providers to serve patients' needs.

Stephan Foster, PharmD, FAPha, discusses which vaccines pharmacists should be providing in addition to the seasonal influenza vaccine.

Robert Granko, PharmD, MBA, discusses the importance of building trust among those who will use data analytics and be affected by its use in health-system pharmacy.

Stephen F. Eckel, PharmD, MHA, discusses how the formation of accountable care organizations will affect health-system pharmacy and allow pharmacists to expand their range of practice.

Jonathan G. Marquess, PharmD, CDE, discusses the role that pharmacists can play in helping patients improve management of their diabetes.

Joe Moose, PharmD, discusses how his pharmacy has used technology to monitor medication adherence and to demonstrate to patients and physicians how big a problem it can be.

Steven Lucio of Novation discusses how Teva's Granix (tbo-filgrastim), which was filed through a 351(a) pathway, was approved for only 1 indication--and it was not the indication considered to be the "most definitive" for that particular product.

Aimee Tharaldson of Express Scripts explains why some hepatitis C patients who do not have signs of active disease may want to wait to receive treatment until later this year and early next year, when the FDA is expected to approve sofosbuvir and simeprevir for the treatment of this condition.

Last year there were 11 new cancer drugs approved, and so far this year, 6 oncology medications have been approved, notes Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts.

The process of adding biosimilars to formularies will be much more rigorous than what the industry is accustomed to seeing in the generic molecule space, asserted Steven Lucio, senior director, Clinical Solutions and Pharmacy Program Development at Novation.

David G. Miller, RPh, discusses concerns regarding the regulatory status of compounding medications for office use by physicians or dentists.

We will see a new wave of oral antiviral hepatitis C medicines hitting the market towards the end of this year and the beginning of next year, noted Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts.

Stephan Foster, PharmD, FAPha, explains why pharmacists are providing an increasing portion of vaccinations.

David G. Miller, RPh, discusses H.R. 3204, the Drug Quality and Security Act, which passed the House of Representatives on September 25, 2013.

Steven Lucio of Novation discusses why now is the time for pharmacists to educate themselves about biosimilars and the complexities surrounding biologic manufacturing.

Mitchell Katz, PhD, executive director, medical research operations at Purdue Pharma L.P., explains the function of a Contract Research Organization (CRO) and its role in drug development.

Jonathan G. Marquess, PharmD, CDE, explains why he decided to focus on caring for diabetes patients at his pharmacy.

Robert Granko, PharmD, MBA, discusses how his hospital system developed a model that used data to determine how pharmacists should be positioned.

Leigh Ann Bruhn, director of Avalere Health, notes that limited distribution for specialty pharmaceuticals can improve a manufacturer's data capture capabilities.

Joe Moose, PharmD, discusses what it means to shift from a volume-driven business to a value-driven business.

Edmund Pezalla, MD, MPH, national medical director, pharmacy policy and strategy at Aetna, explains how drugs that have been deemed "failures" can sometimes become effective treatments for other conditions.

Pharmacy Times Health-System Edition Editor Stephen F. Eckel, PharmD, MHA, describes his most rewarding experiences working with pharmacy students.

In this video, Todd Speranzo of Avella talks about how to create video content that is compelling to patients.

Stephan Foster, PharmD, FAPha, discusses the history of preventive medicine in the the pharmacy.

Robert Granko, PharmD, MBA, discusses the move to use business intelligence and data analytics in health systems to better understand what is driving cost increases.

In this video from the 2013 Armada Specialty Pharmacy Summit, Mark Zitter of Zitter Health Insights discusses stakeholder views on copay cards.

Pharmacy Times Health-System Edition Editor Stephen F. Eckel offers advice to pharmacy students who are considering a career in health-system pharmacy.